Evotec completes acquisition of Rigenerand

An Italian-based cell therapy business has just been bought by Evotec SE, a German therapeutics company.

Evotec just announced the strategic transaction to buy Rigenerand Srl, with the deal, signed in May 2022, now completed.

Based out of Medolla, Italy, the cell technology company working in the field of cGMP manufacturing of cell therapies will operate as Evotec (Modena) Srl going forward.

Acquisition finalized

Massimo Dominici, scientific director of Evotec (Modena) and professor of oncology at the University of Modena said: “We are very pleased that the acquisition of Rigenerand has been finalized and the teams have started working together as one.

“The concept of the Evotec Cell Accelerator is already coming to life and matches what is happening in Modena: enriching the pre-existing know-how through the experienced Evotec team. I am therefore convinced that the field has a new player capable of addressing the challenges of next generation cell therapy products, accelerating their development and manufacturing towards the clinic.”

Cell therapy is a fast-growing and highly promising field of biomedical research with the potential to achieve substantial disease-modifying or even curative effects within a single treatment.

The post Evotec completes acquisition of Rigenerand appeared first on Labiotech.eu.

© Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.


About the Author: Biotech Today

You might like